<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="n95/PMC7079862/results/search/disease/results.xml">
  <result pre="with severe RVIs requiring ICU care present typically with hypoxemic" exact="respiratory failure." post="Oseltamivir is the most widely used neuraminidase inhibitor for"/>
  <result pre="Non-invasive ventilation in patients with severe RVI causing acute hypoxemic" exact="respiratory failure" post="and pneumonia is associated with a high likelihood of"/>
  <result pre="patients with severe RVI causing acute hypoxemic respiratory failure and" exact="pneumonia" post="is associated with a high likelihood of transition to"/>
  <result pre="viruses that can cause severe respiratory viral infections (RVIs) include" exact="influenza" post="A and B viruses, picornaviruses (rhinovirus, enterovirus [e.g., enterovirus"/>
  <result pre="(7%) 3 (3%) 11 (10%) 0 (0%) Schnell 2014 Acute" exact="respiratory failure" post="70, 47 (67%) mechanically ventilated PS, BAL France IFA,"/>
  <result pre="(6%) 4 (6%) 1 (1%) 3 (4%) Legoff 2005 Acute" exact="pneumonia" post="admitted to ICU 41 BAL France Viral culture, IFA,"/>
  <result pre="includes commercial and in-house PCR, RT-PCR, and PCR multiplex, COPD" exact="chronic obstructive pulmonary disease," post="NIV non-invasive ventilation, PS nasopharyngeal specimen including nasopharyngeal or"/>
  <result pre="bronchoalveolar lavage, CAP community-acquired pneumonia, ILI influenza-like illness, HCAP healthcare-associated" exact="pneumonia" post="aMultiple publications exist from the same cohort. We included"/>
  <result pre="infection control precautions a Common respiratory viruses Influenza A and" exact="influenza" post="B Only influenza type A viruses are known to"/>
  <result pre="a Common respiratory viruses Influenza A and influenza B Only" exact="influenza" post="type A viruses are known to have caused pandemics"/>
  <result pre="viruses are known to have caused pandemics Currently circulating seasonal" exact="influenza" post="A viruses in humans: subtype A(H1N1)pdm09 and A(H3N2) strains"/>
  <result pre="viruses in humans: subtype A(H1N1)pdm09 and A(H3N2) strains Currently circulating" exact="influenza" post="B viruses: A/Victoria-like, A/Yamagata-like strains May be associated with"/>
  <result pre="influenza B viruses: A/Victoria-like, A/Yamagata-like strains May be associated with" exact="acute myocardial infarction," post="myocarditis, rhabdomyolysis, acute renal failure, encephalopathy/encephalitis, and other non-pulmonary"/>
  <result pre="Parainfluenza (1-4) Contact Adenoviruses Droplet + contact Uncommon and emerging viruses Avian" exact="influenza" post="A/H5N1, A/H5N6, A/H7N9 and other subtypes Residence in or"/>
  <result pre="b Measles c Incomplete vaccination Characteristic rash. Progressive giant cell" exact="pneumonia" post="without rash may occur in immunocompromised (Hecht’s pneumonia) Airborne"/>
  <result pre="c Incomplete vaccination Characteristic rash. Progressive giant cell pneumonia without" exact="rash" post="may occur in immunocompromised (Hecht’s pneumonia) Airborne Hantaviruses (e.g.,"/>
  <result pre="Standard Varicella-zoster virus c Incomplete vaccination, pregnancy Often with characteristic" exact="rash" post="Airborne + contact Please refer to the online supplement for references"/>
  <result pre="Respiratory infections with other viral pathogens, such as cytomegalovirus and" exact="herpes simplex" post="viruses, are not discussed in this review. Antiviral therapy"/>
  <result pre="patients yielded negative results [ 4, 5]. Antiviral therapeutics for" exact="influenza" post="have been studied most extensively and are discussed briefly"/>
  <result pre="Peramivir is approved by the FDA and EMA for uncomplicated" exact="influenza" post="Laninamivir NAI Influenza A and B Rare Inhaled, single"/>
  <result pre="US, Japan, and over eight other countries Nitazoxanide Host-directed and" exact="influenza" post="HA Influenza and other RVIs Not seen in clinical"/>
  <result pre="recommended. Ribavirin Host-directed effects, transcriptase inhibitor, viral mutagen RSV, influenza," exact="measles" post="other RVIs Not seen in clinical strains Aerosolized, oral,"/>
  <result pre="and SOT patients Anecdotal use of systemic ribavirin in severe" exact="measles" post="and other paramyxovirus infections Not recommended in combination with"/>
  <result pre="transplantation, MERS Middle East Respiratory Syndrome, VZV varicella-zoster virus, HSV" exact="herpes simplex" post="virus, NAI neuraminidase inhibitors, EMA European Medicines Agency, FDA"/>
  <result pre="In an individual participant data meta-analysis of hospitalized patients with" exact="influenza" post="A(H1N1)pdm09 virus infection ( n = 29 234 patients from 78 studies),"/>
  <result pre="later treatment [ 7]. Observational data also indicate reduction in" exact="influenza" post="A(H5N1)-associated mortality with timely oseltamivir treatment before the onset"/>
  <result pre="A(H5N1)-associated mortality with timely oseltamivir treatment before the onset of" exact="respiratory failure" post="[ 8]. The importance of timing of oseltamivir treatment"/>
  <result pre="an observational study of 1950 patients admitted to ICUs with" exact="influenza" post="A(H1N1)pdm09, which showed a trend toward improved survival for"/>
  <result pre="and Drug Administration-approved NAI drugs for the treatment of seasonal" exact="influenza" post="[ 10]. Duration of treatment is traditionally 5 days,"/>
  <result pre="to 10 days for severely ill patients with ARDS or" exact="pneumonia" post="or those who are immunocompromised [ 10]. This approach"/>
  <result pre="[ 10]. This approach is supported by data showing slow" exact="influenza" post="viral clearance from the lower respiratory tract in critically"/>
  <result pre="from the lower respiratory tract in critically ill patients with" exact="influenza" post="A(H1N1)pdm09 [ 16]. Of concern is the recent observation"/>
  <result pre="blockage of the ventilator circuit. Peramivir is the only intravenous" exact="influenza" post="antiviral agent currently approved by the US Food and"/>
  <result pre="agents appear to have comparable activity to oseltamivir in hospitalized" exact="influenza" post="patients, although one RCT comparing two dose levels of"/>
  <result pre="a clinical benefit with intravenous peramivir in hospitalized patients with" exact="influenza" post="[ 19]. Because its spectrum of activity includes most"/>
  <result pre="oseltamivir-resistant viruses, intravenous zanamivir is indicated for treatment of severe" exact="influenza" post="A or B when the patient’s influenza virus is"/>
  <result pre="treatment of severe influenza A or B when the patient’s" exact="influenza" post="virus is known or suspected to be resistant to"/>
  <result pre="3). Baloxavir Two phase III trials in non-hospitalized patients with" exact="influenza" post="found that single-dose baloxavir was superior to placebo in"/>
  <result pre="found that single-dose baloxavir was superior to placebo in alleviating" exact="influenza" post="symptoms, and was superior to both oseltamivir and placebo"/>
  <result pre="Data on baloxavir’s pharmacokinetics and optimal dose regimen in critical" exact="influenza" post="illness leading to ICU admission are needed [ 20]."/>
  <result pre="inconsistent results. In an open-label RCT of hospitalized patients with" exact="influenza" post="( n = 107), early combination therapy with clarithromycin, naproxen, and"/>
  <result pre="not associated with improved survival in critically ill patients with" exact="influenza" post="A(H1N1)pdm09 [ 23]. In patients with MERS ( n = 349),"/>
  <result pre="with the cyclooxygenase inhibitor flufenamic acid in hospitalized patients with" exact="influenza" post="is underway (NCT03238612). In addition, macrolides are also examined"/>
  <result pre="fungal infection and the emergence of antiviral resistance in influenza-associated" exact="pneumonia" post="or ARDS [ 25]. A study ( n = 607) that"/>
  <result pre="confounders found no independent influence of corticosteroids on mortality of" exact="influenza" post="[ 26]. The IDSA recommends against corticosteroid adjunctive therapy"/>
  <result pre="The IDSA recommends against corticosteroid adjunctive therapy in patients with" exact="influenza" post="unless clinically indicated for other reasons [ 10]. In"/>
  <result pre="Cyclooxygenase-2 inhibitors Cyclooxygenase-2 may modulate excessive pro-inflammatory responses in severe" exact="influenza" post="[ 30]. In addition to the above study of"/>
  <result pre="mortality and cytokine levels, although not viral titers, in hospitalized" exact="influenza" post="A(H3N2) patients without increased adverse effects [ 31]. Sirolimus"/>
  <result pre="oseltamivir have shown inconsistent effects in murine models of severe" exact="influenza" post="[ 32, 33]. Sirolimus also can modulate inflammatory responses"/>
  <result pre="treatment with sirolimus compared to no sirolimus in patients with" exact="influenza" post="A(H1N1) pneumonia receiving invasive mechanical ventilation (in addition to"/>
  <result pre="sirolimus compared to no sirolimus in patients with influenza A(H1N1)" exact="pneumonia" post="receiving invasive mechanical ventilation (in addition to oseltamivir and"/>
  <result pre="sirolimus without systemic corticosteroids is planned among patients hospitalized with" exact="influenza" post="(NCT03901001). Statins Because of the putative anti-inflammatory effects, statins"/>
  <result pre="anti-inflammatory effects, statins have been proposed as adjunctive therapy in" exact="influenza" post="(NCT02056340), although large clinical trials in patients in ARDS"/>
  <result pre="immunotherapies have been added to neuraminidase inhibitor treatment in hospitalized" exact="influenza" post="patients have yielded inconsistent results. A small randomized-controlled trial"/>
  <result pre="small randomized-controlled trial ( n = 35) demonstrated that treatment of severe" exact="influenza" post="A(H1N1)pdm09 patients with hyperimmune globulin (H-IVIG) containing high titers"/>
  <result pre="Two recent phase III trials have been completed in seasonal" exact="influenza" post="patients. The FLU-IVIG RCT found no overall effect of"/>
  <result pre="clinical benefits were noted in the subgroup of patients with" exact="influenza" post="B virus infection [ 38]. The second trial of"/>
  <result pre="antibody therapies may not significantly improve outcomes in severe seasonal" exact="influenza" post="A, although their possible value in treating severe RVI"/>
  <result pre="although their possible value in treating severe RVI by novel" exact="influenza" post="strains remains to be determined. Vitamin C The recent"/>
  <result pre="often with RVI. Co-infection with Staphylococcus aureus is common with" exact="influenza" post="pneumonia and can be especially virulent [ 10]. The"/>
  <result pre="with RVI. Co-infection with Staphylococcus aureus is common with influenza" exact="pneumonia" post="and can be especially virulent [ 10]. The recent"/>
  <result pre="antibacterial therapy to be initially prescribed for adults with community-acquired" exact="pneumonia" post="who test positive for influenza [ 10]. The guidelines"/>
  <result pre="prescribed for adults with community-acquired pneumonia who test positive for" exact="influenza" post="[ 10]. The guidelines provide details on when to"/>
  <result pre="guidance for de-escalation of antibacterial therapy in patients with confirmed" exact="influenza" post="[ 10]. Clinicians should be aware of the reports"/>
  <result pre="Clinicians should be aware of the reports of invasive pulmonary" exact="aspergillosis" post="in severely ill influenza patients especially those with underlying"/>
  <result pre="of the reports of invasive pulmonary aspergillosis in severely ill" exact="influenza" post="patients especially those with underlying conditions or receiving corticosteroids,"/>
  <result pre="receiving corticosteroids, although up to 30% of patients with influenza-associated" exact="aspergillosis" post="had been previously healthy [ 41]. Supportive care Patients"/>
  <result pre="Supportive care Patients with severe RVI present typically with pneumonia," exact="acute respiratory distress syndrome" post="(ARDS), decompensated heart failure, or exacerbation of chronic lung"/>
  <result pre="distress syndrome (ARDS), decompensated heart failure, or exacerbation of chronic" exact="lung disease;" post="leading frequently to acute hypoxemic, and less commonly hypercapnic,"/>
  <result pre="disease; leading frequently to acute hypoxemic, and less commonly hypercapnic," exact="respiratory failure." post="Except for several influenza and novel coronavirus studies noted"/>
  <result pre="hypoxemic, and less commonly hypercapnic, respiratory failure. Except for several" exact="influenza" post="and novel coronavirus studies noted below, most of the"/>
  <result pre="not documented specific RVIs. In many ARDS trials, patients with" exact="pneumonia" post="constituted a majority of enrolled patients; but detailed description"/>
  <result pre="There are general pathophysiologic and clinical similarities between ARDS and" exact="pneumonia" post="caused by severe RVIs and those due to other"/>
  <result pre="RVI are limited. In patients with severe RVI resulting in" exact="chronic obstructive pulmonary disease" post="(COPD) exacerbations or cardiogenic pulmonary edema, NIV may be"/>
  <result pre="resulting in chronic obstructive pulmonary disease (COPD) exacerbations or cardiogenic" exact="pulmonary edema," post="NIV may be effective in reducing the need of"/>
  <result pre="However, NIV in patients with severe RVI causing acute hypoxemic" exact="respiratory failure" post="and pneumonia is of uncertain benefit. Observational studies reported"/>
  <result pre="patients with severe RVI causing acute hypoxemic respiratory failure and" exact="pneumonia" post="is of uncertain benefit. Observational studies reported variable results"/>
  <result pre="studies reported variable results for NIV in patients with severe" exact="influenza" post="A(H1N1)pdm09 with some reporting NIV failure in up to"/>
  <result pre="observational study of 1898 critically ill patients with acute hypoxemic" exact="respiratory failure" post="due to influenza, 806 underwent initial NIV, and 56.8%"/>
  <result pre="patients in early stages and milder forms of acute hypoxemic" exact="respiratory failure," post="excluding those in shock or multiorgan failure, with the"/>
  <result pre="to NIV to prevent intubation in patients with acute hypoxemic" exact="respiratory failure." post="In one trial ( n = 310, 72% community-acquired pneumonia), treatment"/>
  <result pre="49]. A small cohort of patients with severe RVI with" exact="influenza" post="A(H1N1)pdm09 ( n = 25) showed that high-flow nasal cannula was"/>
  <result pre="relatively high mean airway pressures [ 53]. In patients with" exact="influenza" post="A(H1N1)pdm09 influenza, HFOV has been used as a rescue"/>
  <result pre="reported lower hospital mortality among patients with ARDS related to" exact="influenza" post="A(H1N1)pdm09 with transfer to an ECMO center compared with"/>
  <result pre="with severe RVI. Myocardial involvement is not uncommon with severe" exact="influenza" post="A or B virus infection, and multiple studies have"/>
  <result pre="virus infection, and multiple studies have shown an association between" exact="influenza" post="and acute myocardial infection and myocarditis [ 66– 68]."/>
  <result pre="shown an association between influenza and acute myocardial infection and" exact="myocarditis" post="[ 66– 68]. Echocardiographic findings often include right- and"/>
  <result pre="are recommended; droplet precautions may be discontinued when adenovirus and" exact="influenza" post="have been ruled out. For patients with a history"/>
  <result pre="days) to countries with active outbreaks of SARS, MERS, or" exact="avian influenza," post="airborne plus contact precautions and eye protection are recommended."/>
  <result pre="settings have not shown significant differences in protection from laboratory-confirmed" exact="influenza" post="or other RVIs [ 72, 73]. The relevance of"/>
  <result pre="transmission when caring for patients with severe RVIs include annual" exact="influenza" post="vaccination of healthcare workers, adherence to standard precautions, including"/>
  <result pre="less effective than hand washing with running water in inactivating" exact="influenza" post="virus in undried mucus under experimental conditions; [ 75]"/>
  <result pre="funding from GlaxoSmithKline (Data Safety Monitoring Board [DSMB] member for" exact="influenza" post="randomized-controlled trial [RCT]), Celltrion (DSMB chair for influenza RCT),"/>
  <result pre="member for influenza randomized-controlled trial [RCT]), Celltrion (DSMB chair for" exact="influenza" post="RCT), and Vaccitech (DSMB chair for influenza RCTs); he"/>
  <result pre="(DSMB chair for influenza RCT), and Vaccitech (DSMB chair for" exact="influenza" post="RCTs); he received honoraria from World Health Organization (consultant"/>
  <result pre="RCTs); he received honoraria from World Health Organization (consultant on" exact="influenza" post="and emerging viral infections) and the University of Alabama"/>
  <result pre="Sciences, SAB Biotherapeutics, and Regeneron, and for multiple companies on" exact="influenza" post="therapeutics; Cidara, Shionogi, Seqirus, and resTORbio have made charitable"/>
  <result pre="tract virus findings in mechanically ventilated patients with severe community-acquired" exact="pneumonia" post="Clin Infect Dis 2014 59 62 70 10.1093/cid/ciu237 24729498"/>
  <result pre="inhibitors in reducing mortality in patients admitted to hospital with" exact="influenza" post="A H1N1pdm09 virus infection: a meta-analysis of individual participant"/>
  <result pre="Dreyer NA Toovey S Effectiveness of antiviral treatment in human" exact="influenza" post="A(H5N1) infections: analysis of a Global Patient Registry J"/>
  <result pre="TM Treatment with neuraminidase inhibitors for critically ill patients with" exact="influenza" post="A (H1N1)pdm09 Clin Infect Dis 2012 55 1198 1204"/>
  <result pre="SN High-dose versus standard dose oseltamivir for treatment of severe" exact="influenza" post="in adult intensive care unit patients Intensive Care Med"/>
  <result pre="intervention study on higher-dose oseltamivir treatment in adults hospitalized with" exact="influenza" post="a and B infections Clin Infect Dis 2013 57"/>
  <result pre="high-dose versus standard dose oseltamivir in critically ill patients with" exact="influenza" post="J Intensive Care Med 2017 32 574 577 10.1177/0885066616638649"/>
  <result pre="of oseltamivir carboxylate in critically ill patients with pandemic (H1N1)" exact="influenza" post="Ther Drug Monit 2012 34 171 175 10.1097/FTD.0b013e318248672c 22354159"/>
  <result pre="and inflammatory response patterns in adults hospitalized for pandemic 2009" exact="influenza" post="A(H1N1) virus pneumonia Antivir Ther 2011 16 237 247"/>
  <result pre="patterns in adults hospitalized for pandemic 2009 influenza A(H1N1) virus" exact="pneumonia" post="Antivir Ther 2011 16 237 247 10.3851/IMP1722 21447873 17."/>
  <result pre="S Mekontso DA de Prost N Oseltamivir resistance in severe" exact="influenza" post="A(H1N1)pdm09 pneumonia and acute respiratory distress syndrome: a French"/>
  <result pre="DA de Prost N Oseltamivir resistance in severe influenza A(H1N1)pdm09" exact="pneumonia" post="and acute respiratory distress syndrome: a French multicenter observational"/>
  <result pre="P Sheridan WP Evaluation of intravenous peramivir for treatment of" exact="influenza" post="in hospitalized patients Clin Infect Dis 2014 59 e172"/>
  <result pre="T LB16. Phase 3 trial of baloxavir marboxil in high-risk" exact="influenza" post="patients (CAPSTONE-2 study) Open Forum Infect Dis 2018 5"/>
  <result pre="of clarithromycin-naproxen-oseltamivir combination in the treatment of patients hospitalized for" exact="influenza" post="A(H3N2) infection: an open-label randomized, controlled, phase IIb/III trial"/>
  <result pre="of bacterial co-infection in critically ill H1N1 patients with primary" exact="viral pneumonia" post="Intensive Care Med 2013 39 693 702 10.1007/s00134-013-2829-8 23344833"/>
  <result pre="bacterial co-infection in critically ill H1N1 patients with primary viral" exact="pneumonia" post="Intensive Care Med 2013 39 693 702 10.1007/s00134-013-2829-8 23344833"/>
  <result pre="HNC The influence of corticosteroid treatment on the outcome of" exact="influenza" post="A(H1N1pdm09)-related critical illness Crit Care 2016 20 75 10.1186/s13054-016-1230-8"/>
  <result pre="of cyclooxygenase-2-mediated proinflammatory cascade: a mechanism for the pathogenesis of" exact="avian influenza" post="H5N1 infection J Infect Dis 2008 198 525 535"/>
  <result pre="cyclooxygenase-2-mediated proinflammatory cascade: a mechanism for the pathogenesis of avian" exact="influenza" post="H5N1 infection J Infect Dis 2008 198 525 535"/>
  <result pre="Chan KH, Yuen KY. ECCMID 2019. O0815 Treatment of severe" exact="influenza" post="A infection with celecoxib. https://www.escmid.org. Accessed 14 Sep 2019"/>
  <result pre="Huang YL Dutta A Rapamycin adjuvant and exacerbation of severe" exact="influenza" post="in an experimental mouse model Sci Rep 2017 7"/>
  <result pre="sirolimus, and steroids improves outcomes in patients with severe H1N1" exact="pneumonia" post="and acute respiratory failure Crit Care Med 2014 42"/>
  <result pre="improves outcomes in patients with severe H1N1 pneumonia and acute" exact="respiratory failure" post="Crit Care Med 2014 42 313 321 10.1097/CCM.0b013e3182a2727d 24105455"/>
  <result pre="Investigators H-, Irish Critical Care Trials G Simvastatin in the" exact="acute respiratory distress syndrome" post="N Engl J Med 2014 371 1695 1703 10.1056/NEJMoa1403285"/>
  <result pre="multicenter double-blind randomized controlled trial for patients with severe 2009" exact="influenza" post="A(H1N1) infection Chest 2013 144 464 473 10.1378/chest.12-2907 23450336"/>
  <result pre="JA Ramírez-Hinojosa JP Anti-influenza hyperimmune intravenous immunoglobulin for adults with" exact="influenza" post="A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled"/>
  <result pre="Anti-influenza immune plasma for the treatment of patients with severe" exact="influenza" post="A: a randomised, double-blind, phase 3 trial Lancet Respir"/>
  <result pre="T van de Veerdonk F Influenza coinfection: be(a)ware of invasive" exact="aspergillosis" post="Clin Infect Dis 2019 70 349 350 10.1093/cid/ciz391 42."/>
  <result pre="SMOTTF Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute" exact="respiratory failure" post="Eur Respir J 2017 50 1602426 10.1183/13993003.02426-2016 28860265 43."/>
  <result pre="Critical Care Trials Group HNC Critically ill patients with 2009" exact="influenza" post="A(H1N1) infection in Canada JAMA 2009 302 1872 1879"/>
  <result pre="for noninvasive ventilation failure in critically ill subjects with confirmed" exact="influenza" post="infection Respir Care 2017 62 1307 1315 10.4187/respcare.05481 28698265"/>
  <result pre="of noninvasive positive pressure ventilation in the treatment of acute" exact="respiratory failure" post="in severe acute respiratory syndrome Chest 2004 126 845"/>
  <result pre="pressure ventilation in the treatment of acute respiratory failure in" exact="severe acute respiratory syndrome" post="Chest 2004 126 845 850 10.1378/chest.126.3.845 15364765 46. Fowler"/>
  <result pre="Louie M Tang P Simor AE Stewart TE Transmission of" exact="severe acute respiratory syndrome" post="during intubation and mechanical ventilation Am J Respir Crit"/>
  <result pre="Network R High-flow oxygen through nasal cannula in acute hypoxemic" exact="respiratory failure" post="N Engl J Med 2015 372 2185 2196 10.1056/NEJMoa1503326"/>
  <result pre="acute respiratory infection: a cohort study in patients with 2009" exact="influenza" post="A/H1N1v J Crit Care 2012 27 434 439 10.1016/j.jcrc.2012.04.006"/>
  <result pre="Experience with high frequency oscillation ventilation during the 2009 H1N1" exact="influenza" post="pandemic in Australia and New Zealand Anaesth Intensive Care"/>
  <result pre="OT, Canadian Critical Care Trials G High-frequency oscillation in early" exact="acute respiratory distress syndrome" post="N Engl J Med 2013 368 795 805 10.1056/NEJMoa1215554"/>
  <result pre="Rowan K Cuthbertson BH collab: Group OS High-frequency oscillation for" exact="acute respiratory distress syndrome" post="N Engl J Med 2013 368 806 813 10.1056/NEJMoa1215716"/>
  <result pre="Severity of hypoxemia and effect of high-frequency oscillatory ventilation in" exact="acute respiratory distress syndrome" post="Am J Respir Crit Care Med 2017 196 727"/>
  <result pre="L Ayzac L collab: Group PS Prone positioning in severe" exact="acute respiratory distress syndrome" post="N Engl J Med 2013 368 2159 2168 10.1056/NEJMoa1214103"/>
  <result pre="Morange S Roch A Investigators AS Neuromuscular blockers in early" exact="acute respiratory distress syndrome" post="N Engl J Med 2010 363 1107 1116 10.1056/NEJMoa1005372"/>
  <result pre="CA Yealy DM Angus DC Early neuromuscular blockade in the" exact="acute respiratory distress syndrome" post="N Engl J Med 2019 380 1997 2008 10.1056/NEJMoa1901686"/>
  <result pre="Eolia Trial Group R, Ecmonet Extracorporeal membrane oxygenation for severe" exact="acute respiratory distress syndrome" post="N Engl J Med 2018 378 1965 1975 10.1056/NEJMoa1800385"/>
  <result pre="D Slutsky AS Combes A Extracorporeal membrane oxygenation for severe" exact="acute respiratory distress syndrome" post="and posterior probability of mortality benefit in a post"/>
  <result pre="membrane oxygenation center and mortality among patients with severe 2009" exact="influenza" post="A(H1N1) JAMA 2011 306 1659 1668 10.1001/jama.2011.1471 21976615 64."/>
  <result pre="Grissom CK Right and left heart failure in severe H1N1" exact="influenza" post="A infection Eur Respir J 2011 37 112 118"/>
  <result pre="CP Shieh WJ Uyeki TM Zaki SR Myocardial injury and" exact="bacterial pneumonia" post="contribute to the pathogenesis of fatal influenza B virus"/>
  <result pre="Shieh WJ Uyeki TM Zaki SR Myocardial injury and bacterial" exact="pneumonia" post="contribute to the pathogenesis of fatal influenza B virus"/>
  <result pre="injury and bacterial pneumonia contribute to the pathogenesis of fatal" exact="influenza" post="B virus infection J Infect Dis 2012 205 895"/>
  <result pre="M Zahariadis G Gubbay JB Acute myocardial infarction after laboratory-confirmed" exact="influenza" post="infection N Engl J Med 2018 378 345 353"/>
  <result pre="A Krueger H Simon AR Successful treatment of novel H1N1" exact="influenza" post="related fulminant myocarditis with extracorporeal life support J Cardiothorac"/>
  <result pre="Simon AR Successful treatment of novel H1N1 influenza related fulminant" exact="myocarditis" post="with extracorporeal life support J Cardiothorac Surg 2011 6"/>
  <result pre="TM Pi Res N95 respirators vs medical masks for preventing" exact="influenza" post="among health care personnel: a randomized clinical trial JAMA"/>
  <result pre="A Walter SD Surgical mask vs N95 respirator for preventing" exact="influenza" post="among health care workers: a randomized trial JAMA 2009"/>
  <result pre="reduced effectiveness of current hand hygiene against infectious mucus from" exact="influenza" post="virus-infected patients mSphere 2019 4 e00474 e00479 31533996 76."/>
 </snippets>
</snippetsTree>
